CRISPR THERAPEUTICS AG (CRSP:NASDAQ)
$51.72 -0.54 (-1.0333%)
Analysed CRISPR THERAPEUTICS AG (CRSP:NASDAQ) News Sources
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
28-08-2026
yahoo.com
Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?
02-09-2026
yahoo.com
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As CTX310 Data Impresses
02-09-2026
yahoo.com
2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026
02-09-2026
fool.com
CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
08-09-2026
yahoo.com
Where Will CRISPR Therapeutics Stock Be in 5 Years?
08-09-2026
fool.com
Why CRISPR Therapeutics Stock Rocked the Market Last Month
08-09-2026
fool.com
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
11-09-2026
fool.com
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
11-09-2026
fool.com
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
11-09-2026
fool.com
What is the current price of CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The current price of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is $51.72.
CRISPR THERAPEUTICS AG (CRSP:NASDAQ) absolute price change since previous trading day?
The absolute price change of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) since the previous trading day is $-0.54.
CRISPR THERAPEUTICS AG (CRSP:NASDAQ) percentage price change since previous trading day?
The percentage price change of CRISPR THERAPEUTICS AG (CRSP:NASDAQ) since the previous trading day is -1.0333%.
What is the most recent average sentiment score for CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The most recent average sentiment score for CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for CRISPR THERAPEUTICS AG (CRSP:NASDAQ)?
The most recent sentiment for CRISPR THERAPEUTICS AG (CRSP:NASDAQ) is .
SEC-8K** Filing Available For CRISPR THERAPEUTICS AG (CRSP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.